Literature DB >> 1311092

The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors.

E W Raines1, T F Lane, M L Iruela-Arispe, R Ross, E H Sage.   

Abstract

Interactions among growth factors, cells, and extracellular matrix are critical to the regulation of directed cell migration and proliferation associated with development, wound healing, and pathologic processes. Here we report the association of PDGF-AB and -BB, but not PDGF-AA, with the extracellular glycoprotein SPARC. Complexes of SPARC and 125I-labeled PDGF-BB or -AB were specifically immunoprecipitated by anti-SPARC immunoglobulins. 125I-PDGF-BB and -AB also bound specifically to SPARC that was immobilized on microtiter wells or bound to nitrocellulose after transfer from SDS/polyacrylamide gels. The binding of PDGF-BB to SPARC was pH-dependent; significant binding was detectable only above pH 6.6. The interaction of SPARC with specific dimeric forms of PDGF affected the activity of this mitogen. SPARC inhibited the binding of PDGF-BB and PDGF-AB, but not PDGF-AA, to human dermal fibroblasts in a dose-dependent manner. The expression of SPARC and PDGF was minimal in most normal adult tissues but was increased after injury. Enhanced expression of both PDGF-B chain and SPARC was seen in advanced lesions of atherosclerosis. We suggest that the coordinate expression of SPARC and PDGF-B-containing dimers following vascular injury may regulate the activity of specific dimeric forms of PDGF in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311092      PMCID: PMC48433          DOI: 10.1073/pnas.89.4.1281

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  The transforming growth factor-beta receptor type III is a membrane proteoglycan. Domain structure of the receptor.

Authors:  S Cheifetz; J L Andres; J Massagué
Journal:  J Biol Chem       Date:  1988-11-15       Impact factor: 5.157

2.  The effects of platelet-derived growth factor in cultured microvessel endothelial cells.

Authors:  R S Bar; M Boes; B A Booth; B L Dake; S Henley; M N Hart
Journal:  Endocrinology       Date:  1989-04       Impact factor: 4.736

3.  Two classes of PDGF receptor recognize different isoforms of PDGF.

Authors:  C E Hart; J W Forstrom; J D Kelly; R A Seifert; R A Smith; R Ross; M J Murray; D F Bowen-Pope
Journal:  Science       Date:  1988-06-10       Impact factor: 47.728

4.  Isolation and characterization of native adult osteonectin.

Authors:  R W Romberg; P G Werness; P Lollar; B L Riggs; K G Mann
Journal:  J Biol Chem       Date:  1985-03-10       Impact factor: 5.157

5.  Calcium binding domains and calcium-induced conformational transition of SPARC/BM-40/osteonectin, an extracellular glycoprotein expressed in mineralized and nonmineralized tissues.

Authors:  J Engel; W Taylor; M Paulsson; H Sage; B Hogan
Journal:  Biochemistry       Date:  1987-11-03       Impact factor: 3.162

6.  The high molecular weight receptor to transforming growth factor-beta contains glycosaminoglycan chains.

Authors:  P R Segarini; S M Seyedin
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

7.  Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular proliferative lesions.

Authors:  K Rubin; A Tingström; G K Hansson; E Larsson; L Rönnstrand; L Klareskog; L Claesson-Welsh; C H Heldin; B Fellström; L Terracio
Journal:  Lancet       Date:  1988-06-18       Impact factor: 79.321

8.  The B chain of PDGF alone is sufficient for mitogenesis.

Authors:  J D Kelly; E W Raines; R Ross; M J Murray
Journal:  EMBO J       Date:  1985-12-16       Impact factor: 11.598

9.  Binding of different dimeric forms of PDGF to human fibroblasts: evidence for two separate receptor types.

Authors:  C H Heldin; G Bäckström; A Ostman; A Hammacher; L Rönnstrand; K Rubin; M Nistér; B Westermark
Journal:  EMBO J       Date:  1988-05       Impact factor: 11.598

10.  Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation.

Authors:  O Saksela; D Moscatelli; A Sommer; D B Rifkin
Journal:  J Cell Biol       Date:  1988-08       Impact factor: 10.539

View more
  94 in total

1.  Osteonectin/SPARC secreted by RPE and localized to the outer plexiform layer of the monkey retina.

Authors:  I R Rodríguez; E F Moreira; D Bok; M Kantorow
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-08       Impact factor: 4.799

2.  Characterization of SMOC-2, a modular extracellular calcium-binding protein.

Authors:  Christian Vannahme; Silke Gösling; Mats Paulsson; Patrik Maurer; Ursula Hartmann
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

3.  Integrin β4 regulates SPARC protein to promote invasion.

Authors:  Kristin D Gerson; Jeffrey R Shearstone; V S R Krishna Maddula; Bruce E Seligmann; Arthur M Mercurio
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

Review 4.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

5.  PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling.

Authors:  Stacey L Thomas; Ridwan Alam; Nancy Lemke; Lonni R Schultz; Jorge A Gutiérrez; Sandra A Rempel
Journal:  Neuro Oncol       Date:  2010-05-14       Impact factor: 12.300

Review 6.  The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.

Authors:  Anguo Liu; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  Microvasc Res       Date:  2008-10-01       Impact factor: 3.514

7.  Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.

Authors:  Shanna A Arnold; Lee B Rivera; Andrew F Miller; Juliet G Carbon; Sean P Dineen; Yang Xie; Diego H Castrillon; E Helene Sage; Pauli Puolakkainen; Amy D Bradshaw; Rolf A Brekken
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

8.  SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling.

Authors:  Jing Nie; E Helene Sage
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

9.  SPARC/osteonectin mRNA is induced in blood vessels following injury to the adult rat cerebral cortex.

Authors:  D B Mendis; G O Ivy; I R Brown
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

10.  SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro.

Authors:  R H Pichler; J A Bassuk; C Hugo; M J Reed; E Eng; K L Gordon; J Pippin; C E Alpers; W G Couser; E H Sage; R J Johnson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.